Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 9/20 | 0.57 |
| ▸ | TRPC4 | Q9UBN4 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 10/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19505500 | 0.94 | TRPC5 (0.50) | TRPC5TRPC4KCNH2TRPC1P2RX3 | |
| SCHEMBL19505249 | 0.93 | TRPC5 (0.49) | TRPC5TRPC4KCNH2TRPC1P2RX3 | |
| SCHEMBL19374906 | 0.93 | TRPC5 (0.49) | TRPC5TRPC4KCNH2TRPC1P2RX3 | |
| SCHEMBL19505572 | 0.92 | TRPC4 (0.47) | TRPC5TRPC4KCNH2TRPC1P2RX3 | |
| SCHEMBL18834916 | 0.91 | TRPC4 (0.45) | TRPC5TRPC4KCNH2TRPC1P2RX3 | |
| SCHEMBL19505328 | 0.91 | TRPC5 (0.49) | TRPC5TRPC4KCNH2TRPC1P2RX3 | |
| SCHEMBL24133837 | 0.88 | TRPC5 (0.57) | TRPC5TRPC4KCNH2TRPC1P2RX3 | |
| SCHEMBL21316297 | 0.88 | TRPC4 (0.42) | TRPC5TRPC4KCNH2TRPC1P2RX3 | |
| SCHEMBL21499683 | 0.87 | P2RX3 (0.51) | TRPC5TRPC4KCNH2TRPC1P2RX3 | |
| SCHEMBL19375568 | 0.87 | TRPC4 (0.43) | TRPC5TRPC4KCNH2TRPC1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200345741-A1 | TRPC ION CHANNEL INHIBITORS FOR USE IN THERAPY | UNIVERSITY OF LEEDS (GB) | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345741-A1 | TRPC ION CHANNEL INHIBITORS FOR USE IN THERAPY | TRPC1, TRPC7, TRPC4 | TRPC5 6/4885TRPC4 3/4885KCNH2 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.